Pulmonary disposition of vancomycin in critically ill patients

被引:0
|
作者
H. Georges
O. Leroy
S. Alfandari
B. Guery
M. Roussel-Delvallez
C. Dhennain
G. Beaucaire
机构
[1] Hôpital Chatilliez,Service Universitaire de Réanimation Médicale et Maladies Infectieuses
[2] Lille University Medical School,Laboratoire de Bacteriologie, Hôpital A. Calmette
[3] Hôpital Chatilliez,Laboratoire de Bacteriologie
关键词
Internal Medicine; Pneumonia; Plasma Concentration; Plasma Level; Minimum Inhibitory Concentration;
D O I
暂无
中图分类号
学科分类号
摘要
Vancomycin penetration in epithelium lining fluid was studied in ten mechanically ventilated patients with methicillin-resistantStaphylococcus aureus pneumonia 24 hours after the onset of treatment. Vancomycin was given intravenously at a daily dose of 30 mg/kg. Vancomycin levels were detectable in four patients (range, 1–2.77 μg/ml). Concordance between high plasma concentrations (> 20 μg/ml) and detectable vancomycin levels in epithelium lining fluid was noted. These results suggest that the pulmonary disposition of vancomycin remains low for most patients 24 h after the onset of treatment compared with the minimum inhibitory concentrations for most gram-positive organisms. One therapeutic goal of vancomycin treatment could be to obtain through plasma levels of 20 μg/ml. Further studies are required to determine the clinical relevance of these observations.
引用
下载
收藏
页码:385 / 388
页数:3
相关论文
共 50 条
  • [21] A protocol for the administration of vancomycin by continuous infusion in critically ill patients
    Giles, LJ
    Castro, J
    Turpin, S
    Sherry, T
    Pierre, D
    Beale, RJ
    Wyncoll, D
    INTENSIVE CARE MEDICINE, 2002, 28 : S164 - S164
  • [22] A PHARMACOKINETIC EVALUATION OF VANCOMYCIN AND CEFEPIME IN CRITICALLY ILL NEUROSURGICAL PATIENTS
    Anliker, Lynn
    Foster, Charles
    Kiser, Tyree
    Mueller, Scott
    Sherman, Deb
    MacLaren, Robert
    Neumann, Robert
    Fish, Douglas
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U255 - U255
  • [23] Vasoactive drug influence on vancomycin pharmacokinetics in critically ill patients
    Gratacos, Laura
    Colom, Helena
    Soy, Dolors
    PHARMACY WORLD & SCIENCE, 2010, 32 (02): : 285 - 286
  • [24] Reduction of inappropriate vancomycin (V) use in critically ill patients
    Villman, M
    Dudas, V
    Jacobs, R
    Guglielmo, BJ
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1174 - 1174
  • [25] Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients
    Scandroglio, Anna Mara
    Pieri, Marina
    Nardelli, Pasquale
    Fominskiy, Evgeny
    Calabro, Maria Grazia
    Melisurgo, Giulio
    Ajello, Silvia
    Pappalardo, Federico
    ARTIFICIAL ORGANS, 2021, 45 (09) : 1097 - 1103
  • [26] VANCOMYCIN MULTIPLE-DOSE KINETICS IN CRITICALLY ILL PATIENTS
    NARANG, PK
    CUNNION, RE
    CUTLER, NR
    LESKO, L
    PARRILLO, JE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 216 - 216
  • [27] Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients
    Alvarez, Osvaldo
    Cristian Plaza-Plaza, Jose
    Ramirez, Manuel
    Peralta, Alexis
    Amador, Cristian A.
    Amador, Roberto
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [28] Continuous infusion of vancomycin in critically ill patients: A new trend?
    Wysocki, M
    MEDECINE ET MALADIES INFECTIEUSES, 1997, 27 : 962 - 964
  • [29] VANCOMYCIN DOSING AND INITIAL TROUGH LEVELS IN CRITICALLY ILL PATIENTS
    Parekh, Trisha
    Gowda, Ashwin
    Shah, Shiwan
    Nishi, Shawn
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U265 - U266
  • [30] Vancomycin dosage in critically ill patients undergoing venovenous haemodiafiltration
    Soler, Ana
    Farre, Rosa
    Roglan, Antoni
    Goretti Lopez-Ramos, Maria
    Antonia Mangues, Maria
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 673 - 673